Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis

Human Reproduction

Volumn 28, Issue 5, 2013, Pages 1339-1347

  Rudzitis Auth, J ^a   Menger, M D ^a   Laschke, M W ^a  

^a University of Saarlan   (Germany)

Author keywords

angiogenesis; endometriosis; proliferation; resveratrol; ultrasound

Indexed keywords

CD31 ANTIGEN; CYCLINE; KI 67 ANTIGEN; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ECHOGRAPHY; ENDOMETRIOSIS; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; STROMA CELL; TREATMENT DURATION; VASCULARIZATION;

ANIMALIA; MUS;

EID: 84876540779     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det031     Document Type: Article

References (35)

1. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. Resveratrol: potential as anticancer agent. J Diet Suppl 2012;9: 45-56.
2. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486: 95-102.
3. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5: 493-506. (Pubitemid 44136961)
4. Beaudeux JL, Nivet-Antoine V, Giral P. Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome? Curr Opin Clin Nutr Metab Care 2010;13: 729-736.
5. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner A, Folkman J, D'Amato RJ. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172: 534-544. (Pubitemid 351282038)
6. Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod 2011;84: 106-112.
7. Cao Z, Fang J, Xia C, Shi X, Jiang BH. trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 2004;10: 5253-5263. (Pubitemid 39099800)
8. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6: 389-395. (Pubitemid 30208155)
9. Chen Y, Tseng SH. Review. Pro-and anti-angiogenesis effects of resveratrol. In Vivo 2007;21: 365-370. (Pubitemid 46534292)
10. Feng D, Welker S, Körbel C, Rudzitis-Auth J, Menger MD, Montenarh M, Laschke MW. Protein kinase CK2 is a regulator of angiogenesis in endometriotic lesions. Angiogenesis 2012;15: 243-252.
11. Galle PC. Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am 1989;16: 29-42. (Pubitemid 19054702)
12. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXOtranscription factor. PLoS One 2010;5: e15627.
13. Gramantieri L, Treré D, Chieco P, Lacchini M, Giovannini C, Piscaglia F, Cavallari A, Bolondi L. In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. J Hepatol 2003;39: 997-1003. (Pubitemid 37523772)
14. Groothuis PG, Nap AW, Winterhager E, Grümmer R. Vascular development in endome-triosis. Angiogenesis 2005;8: 147-156.
15. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162: 285-294.
16. Harikumar KB, Kunnumakkara AB, Sethi G, Diagaradjane P, Anand P, Pandey MK, Gelovani J, Krishnan S, Guha S, Aggarwal BB. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 2010;127: 257-268.
17. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl) 2007; 120: 1672-1677. (Pubitemid 47603955)
18. Kaneko H, Anzai T, Morisawa M, Kohno T, Nagai T, Anzai A, Takahashi T, Shimoda M, Sasaki A, Maekawa Y et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011;217: 350-357.
19. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E; ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20: 2698-2704. (Pubitemid 41487622)
20. Körbel C, Menger MD, Laschke MW. Size and spatial orientation of uterine tissue transplants on the peritoneum crucially determine the growth and cyst formation of endometriosis-like lesions in mice. Hum Reprod 2010;25: 2551-2558.
21. Kordek R, Biernat W, Alwasiak J, Liberski PP. Proliferating cell nuclear antigen (PCNA) and Ki-67 immunopositivity in human astrocytic tumours. Acta Neurochir (Wien) 1996;138: 509-512.
22. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13: 331-342. (Pubitemid 47062827)
23. Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update 2012;18: 682-702.
24. Laschke MW, Körbel C, Rudzitis-Auth J, Gashaw I, Reinhardt M, Hauff P, Zollner TM, Menger MD. High-resolution ultrasound imaging: a novel technique for the noninvasive in vivo analysis of endometriotic lesion and cyst formation in small animal models. Am J Pathol 2010; 176: 585-593.
25. Lee B, Lee EJ, Kim DI, Park SK, Kim WJ, Moon SK. Inhibition of proliferation and migration by piceatannol in vascular smooth muscle cells. Toxicol In Vitro 2009;23: 1284-1291.
26. May K, Becker CM. Endometriosis and angiogenesis. Minerva Ginecol 2008; 60: 245-254.
27. Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010;8: 478-500.
28. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci 2011;1215: 22-33.
29. Rudzitis-Auth J, Körbel C, Scheuer C, Menger MD, Laschke MW. Xanthohumol inhibits growth and vascularization of developing endometriotic lesions. Hum Reprod 2012;27: 1735-1744.
30. Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissues into the peritoneal cavity. Am J Obstet Gynecol 1927; 14: 422-469.
31. Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol Nutr Food Res 2012; 56: 7-13.
32. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, Brodszky V, Canis M, Colombo GL, DeLeire T et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum Reprod 2012;27: 1292-1299.
33. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health- A comprehensive review of human clinical trials. Mol Nutr Food Res 2011;55: 1129-1141.
34. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, Chen CK, Lin PY, Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004;10: 2190-2202. (Pubitemid 38375581)
35. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005;4: 1465-1474. (Pubitemid 41556428)